An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

The phrase Make America Great Again doesn’t have to divide us. Let’s reframe it as a challenge to rise to our potential — a ...

The Fed’s monetary policy and Trump administration's trade policies will play a key role in shaping US markets in 2025.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Thrive Global announced today it is working with Eli Lilly and Company to embed behavior change tools and resources onto LillyDirect and into traditional Lilly ...

Hyderabad: Eli Lilly and Company, a multinational pharmaceutical company, announced plans to establish a new global capability centre in Hyderabad on Thursday. The new centre will be named *Lilly ...

Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the company’s behavior-change research and customers’ self-reported health data to ...